Prestin as an Early Biomarker of Hearing Loss in Nasopharyngeal Cancer Patients Undergoing Induction Chemoradiation

<b>Background/Objectives:</b> Nasopharyngeal cancer (NPC) is prevalent in Southeast Asia, Southern China and North Africa. Up to 46% of NPC patients undergoing cisplatin chemoradiation treatment experience irreversible hearing loss. Prestin is a motor protein in the outer hair cells of the cochlea,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Vanessa Y. J. Tan, Ng Jia Hui, Kiattisa Sommat, Thong Jiun Fong, Edward Z. Y. Zhang, Lai Oi Fah, Chia Xin Ni, Ang Mei Kim, Ong Ni Gin, Lim Chwee Ming
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2026-03-01
coleção:	Journal of Otorhinolaryngology, Hearing and Balance Medicine
Assuntos:	ototoxicity biomarker cancer prestin hearing loss tinnitus
Acesso em linha:	https://www.mdpi.com/2504-463X/7/1/14
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!